Cambridge, MA · Founded 2017 · Privately Held (backing)
Developer of brain-penetrant and peripherally-restricted small molecules designed to slow or modify the progression of neurodegenerative and cardiorenal diseases. Eikonizo Therapeutics is based in Cambridge, MA and was founded in 2017. It was valued at $54 million at its later-stage round in Dec 2023, the last priced event on record. It has raised $46.1 million across 2 recorded rounds; the latest was a $371,352 seed round in May 2018.
PMV mark · valuation
$54.0M
Oct 2026
Priced at
its later-stage round
Dec 2023
Total raised
$46.1M
Last round
Seed Round
May 2018
Cap table — not yet on record
Eikonizo Therapeutics's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Eikonizo Therapeutics with a free account
·Watch Eikonizo Therapeutics: the Monday email on marks, rounds and moves
Where does Eikonizo Therapeutics's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Eikonizo Therapeutics's 2 recorded funding rounds.
